Morningstar Investor users sign in here.
TOPIC

MAYNE News & Analysis

Positive outlook despite Mayne's $134m full-year loss
Stocks
Positive outlook despite Mayne's $134m full-year loss
The specialty drug-maker exceeded analysts' expectations on an adjusted basis, despite posting a full-year loss of $133.98 million.
Emma Rapaport | 24 August 2018